Physician profile
Rene Rivera
NPI 1356537054
$13,425.64
in general payments reported to CMS, 2019-2025
36 companies · $2,120 in 2025
The $2,120 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $821 · 2021: $1,506 · 2022: $3,580 · 2023: $1,899 · 2024: $2,030 · 2025: $2,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,933 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,933.01 |
| Education | $115.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,495.60 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Research & Development, LLC | $1,576.79 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,200.80 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $1,020.27 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $989.66 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $877.51 | 2019-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $635.72 | 2019-2025 | |
| Daiichi Sankyo INC. | $535.14 | 2019-2025 | Injectafer |
| Pfizer INC. | $342.46 | 2019-2025 | |
| Celgene Corporation | $327.59 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $295.05 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $219.17 | 2024-2025 | Zymfentra, Vegzelma |
| Regeneron Healthcare Solutions, INC. | $207.99 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $183.06 | 2020-2024 | Linzess |
| Covidien Lp | $158.77 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $153.69 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $129.34 | 2020-2023 | |
| Ferring Pharmaceuticals INC. | $126.26 | 2019-2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $121.77 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $121.03 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $103.99 | 2024-2025 | Iqirvo |
| Redhill Biopharma INC. | $88.47 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $87.93 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $80.47 | 2024-2025 | Zenpep |
| Amgen INC. | $64.43 | 2020-2022 | |
| Shire North American Group INC | $38.11 | 2019 | |
| Fresenius Kabi USA, LLC | $32.46 | 2023 | Idacio |
| Allergan, INC. | $31.64 | 2019-2020 | |
| Genzyme Corporation | $29.65 | 2022 | |
| Alnylam Pharmaceuticals INC. | $29.52 | 2024 | Givlaari |
| Pharmacosmos Therapeutics INC. | $23.07 | 2021 | |
| Novo Nordisk INC | $22.66 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $19.93 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $19.86 | 2024 | Zeposia |
| Dova Pharmaceuticals | $18.17 | 2019 | |
| W. L. Gore & Associates, INC. | $17.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.